Lung adenocarcinoma is the most common histologic subtype of lung cancer in worldwide, accounting for approximately 40% of all lung cancers. This cancer is classified within the broader category of non-small cell lung cancer (NSCLC), which comprises roughly 85% of all lung malignancies. Despite therapeutic advances, lung adenocarcinoma remains the leading cause of cancer death, largely because most cases are diagnosed at an advanced stage. Literature reported a five-year survival of 5.0% among patients with metastatic adenocarcinoma of lung. This case, featuring a rapid three- month complete metabolic response and zero toxicity, constitutes an exceptional, potentially synergistic reaction between Crizotinib, a conventional standard therapy and a complementary therapy, the Siddha medical system.